经食道超声心动图评估特发性房颤左心房左心耳的价值

目的:研究经食道超声心动图(TEE)评估特发性房颤左心房左心耳的临床价值。方法:选择自2015年1月到2016年8月在医院接受诊治的特发性房颤患者100例纳入本次研究,阵发性房颤92例,记为阵发性房颤组;持续性房颤8例,记为持续性房颤组。另选同期在医院进行健康体检的心功能正常志愿者90例作为对照组。利用TEE对受试者进行检查,对比房颤组与对照组的左心房及左心耳参数,是否含有自发性显影(LASEC)的房颤患者的左心房及左心耳参数,利用TEE分析对房颤患者的预后情况。结果:阵发性房颤组左心房的前后径和左右径,左心耳血流最大的排空速度(Lev)均明显小于对照组,左心耳的面积变化率及最大的充盈速度(Lfv)均明显大于对照组,差异有统计学意义(P0.05)。持续性房颤组左心房的前后径和左右径均明显大于对照组,左心耳的面积变化率、Lev及Lfv均明显小于对照组,差异有统计学意义(P0.05)。阵发性房颤组左心房的前后径和左右径均明显小于持续性房颤组,左心耳的面积变化率、Lev及Lfv均明显大于持续性房颤组,差异有统计学意义(P0.05)。有LASEC者左心房的前后径和左右径均明显大于无LASEC者,左心耳的面积变化率、Lev及Lfv均明显小于无LASEC者,差异有统计学意义(P0.05)。100例房颤患者中发现34例LASEC,占34.00%,其中有18例患者合并有左心耳血栓,占18.00%。总计有66例患者接受导管射频消融疗法,占66.00%,均未在术中及术后7d内出现血栓及栓塞并发症。结论:利用TEE对特发性房颤的患者左心房及左心耳进行评估,有利于更好的辅助患者的临床治疗,值得重视。     

New-onset atrial fibrillation in sepsis is associated with increased morbidity and mortality

BackgroundThe development of new-onset atrial fibrillation in sepsis has been associated with adverse outcomes.MethodsA systematic literature search was conducted to retrieve articles that investigated the association of new-onset atrial fibrillation in patients diagnosed with sepsis. The primary outcome of interest was the pooled risk ratio (RR) of in-hospital mortality in patients with new-onset atrial fibrillation and sepsis.ResultsSix studies included 3100 patients with new-onset atrial fibrillation in sepsis and 36,900 patients without new-onset atrial fibrillation in sepsis. The pooled RR for in-hospital mortality was 1.45 (95 % CI 1.32–1.60, p < 0.00001, I^2 =24 %). New-onset atrial fibrillation was also associated with increased ICU mortality, ICU and in-hospital length of stay and stroke. New-onset atrial fibrillation occurred more in the elderly, those with a prior history of cardiovascular and respiratory disease, and those with increased severity of illness.ConclusionProspective randomised trials are needed to clarify the significance of new-onset atrial fibrillation in sepsis, optimal treatment strategies for these patients, and the benefit of systemic anticoagulation. Physicians should be aware that new-onset atrial fibrillation in sepsis is not merely an observed temporary arrhythmia but a marker of poor prognosis and should be managed accordingly.     

永久起搏器程控在心房颤动诊断中的临床应用及意义

摘要 目的：探究永久起搏器程控在心房颤动诊断中的临床应用及意义。方法：选择78例我院收治的心房颤动患者随机分为程控组和非程控组2组,其中观察组患者给与永久起搏器程控诊断,非程控组则仅给植入永久起搏器,但非程控。对比分析两组患者基本资料、房颤负荷、心房与心室起搏比、心房结构重构及左心功能、P波结果;比较永久起搏器程控诊断与临床诊断结果的差异,分析永久起搏器程控在心房颤动诊断敏感度。结果：程控组和非程控组患者的男女比例、年龄、心率失常的类型、存在的基础性疾病以及使用过的治疗药物比较,差异均无统计学意义（P>0.05）;程控组和非程控组患者的房颤负荷、VP值和P波最小时限均显著小于非程控组,AP值、P波最大时限和P波离散度则显著大于非程控组（P<0.05）;程控组和非程控组患者的LAD、RAD、LVEDD和LVEF值在植入前和植入后均不存在显著性差异（P>0.05）。与临床诊断结果比较可以发现,永久起搏器程控对心房颤动检出率为97.44 %,且永久起搏器程控应用于诊断心房颤动敏感度高达98.72 %。结论：对心房颤动患者采用永久起搏器程控进行诊断,可以在心电图检查的各项指标结果上对患者的心房颤动给与准确的判断,具有较高的临床应用价值,值得临床推广使用。     

射频消融改善阵发性和长期持续性心房颤动患者生活质量的研究

目的:比较射频消融对阵发性和长期持续性心房颤动(房颤)患者生活质量的改善。方法:纳入2011年5月至2016年8月接受射频消融治疗的阵发性房颤患者142例和长期持续性房颤61例。消融前和消融后12个月采用健康状况调查简表(SF-36)评估患者生活质量。结果:长期持续性房颤患者年龄及合并高血压和慢性心功能不全的比例高于阵发性房颤组。消融后12个月,两组患者心理健康(MCS)和生理健康(PCS)评分均显著提高(P0.01)。长期持续性房颤患者MCS和PCS的改善幅度显著高于阵发性房颤组(P0.01)。房颤未复发患者生活质量的提高幅度显著高于复发患者(P0.01)。结论:射频消融改善长期持续性房颤患者生活质量的幅度高于阵发性房颤,房颤复发将影响患者的生活质量。     

左心耳封堵术后房颤患者生活质量评价及其影响因素研究

摘要 目的：探讨左心耳封堵术（LAAC）术后对房颤（AF）患者的生活质量的影响,并分析其影响因素。方法：回顾性分析兰州大学第二医院2019年3月至2022年3月期间接受LAAC治疗的213例AF患者的临床资料。根据简明健康调查量表（SF-36）将213例LAAC术后AF患者分为低生活质量组（总分≤50分,n=107）和高生活质量组（总分＞50分,n=106）。收集并比较AF患者术前基线资料、实验室资料和影像学资料。采用多因素Logistic回归模型分析LAAC术后AF患者生活质量的影响因素。结果：低生活质量组心房颤动血栓发生危险度（CHA2DS2-VASc）评分高于高生活质量组（P<0.05）。低生活质量组的凝血酶原时间百分比高于高生活质量组（P<0.05）。高生活质量组红细胞水平高于低生活质量组（P<0.05）。高生活质量组的左心室射血分数（LVEF）高于低生活质量组（P<0.05）。多因素Logistic回归分析结果显示：CHA2DS2-VASc评分偏高、LVEF偏低是影响LAAC术后AF患者生活质量的危险因素（P<0.05）。结论：CHA2DS2-VASc评分偏高、LVEF偏低是影响LAAC术后AF患者生活质量的危险因素,可降低LAAC术后AF患者的生活质量。     

脂肪因子瘦素和内脂素与心房颤动关系的研究

摘要 目的：心房颤动（Atrial fibrillation,AF）是最常见的心律失常之一,其发生机制目前尚未完全阐明。多项研究表明脂肪因子（Adipokines）中的瘦素（leptin）、内脂素（Visfatin）与心血管疾病的关系密切,本研究拟探讨瘦素、内脂素与心房颤动的关系。方法：本研究通过收集检测AF组、窦性心律组外周血及心外膜脂肪组织,检测瘦素、内脂素分泌水平来探讨瘦素、内脂素与AF发生的相关性。结果：房颤组血清内脂素的平均浓度为15.95±10.44 ng/mL,窦性心律组为20.28±12.90 ng/mL（P=0.169）;房颤组血清瘦素的平均浓度为1.48 ng/mL,窦律组为2.56 ng/mL（P=0.0027）,窦性心律组血清瘦素水平明显高于心房颤动组;心外膜脂肪组织中,瘦素在房颤组中的表达量显著低于窦性心律组（P=0.032）,内脂素在两组中的表达无显著统计学差异（P=0.06）。结论：临床患者外周血血清及心外膜脂肪组织中高水平的瘦素可能降低房颤的发生率,然而,内脂素与房颤可能不具有相关性。     

NT-proBNP对胺碘酮用于急诊阵发房颤复律疗效的预测价值

目的:研究N末端B型利钠肽原(N-terminal pro B-type natriuretic peptide, NT-proBNP)对胺碘酮用于急诊阵发性非瓣膜病心房颤动疗效的预测价值。方法:收集2016-2017年于宣武医院急诊科诊断为阵发性非瓣膜病房颤(发病48h内)的患者共110例,记录所有患者人院时一般资料、既往病史、临床症状体征、实验室数据及测定肌钙蛋白I(Troponin-I, TnI)水平和基线NT-proBNP水平,均给予胺碘酮静脉转复治疗。按照胺碘酮转复情况分为成功组和失败组。结果:静脉应用胺碘酮成功转复91例(82.7%),平均转复时间8.15小时(SD10.16),转复失败者24 h内心室率均控制在100次/min以下,均无严重不良反应。成功组血浆基线NT-pro BNP水平显著低于失败组(P0.05);而两组患者性别、年龄、入室血压、心室率、胸痛、房颤持续时间、入室心电图ST段压低、Tn I水平、冠心病史、高血压、糖尿病、房颤史比较差异均无统计学意义(P0.05)。二元logistic回归分析显示NT-proBNP的自然对数,即In(NT-proBNP)为急诊房颤胺碘酮复律疗效的主要影响因素。结论:对于非瓣膜病房颤急性发作48 h的患者,胺碘酮转复是安全有效的;基线NT-proBNP水平是药物复律成功的重要预测因子,如基线NT-proBNP水平较高,则复律成功率低,为了避免药物的不良反应,可考虑控制心室率,而不是复律治疗。     

Occurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient records

Background  

Chronic atrial fibrillation is a prevalent cardiac disorder. The literature indicates varying proportions of those treated with anticoagulants, and varying intensity of anticoagulation. Electronic patient records are providing us with clinical data concerning management of anticoagulant treatment in real-life practice that is useful for audits. We aimed to assess warfarin treatment for chronic atrial fibrillation in primary health care with regard to prevalence, incidence, the proportion treated and the quality of anticoagulation control.     

胺碘酮治疗老年急性心肌梗死伴心房颤动的临床研究

目的:探究胺碘酮治疗老年急性心肌梗死(AMI)伴心房颤动的疗程疗效。方法:选取于2014年1月-2016年6月来我院诊治的AMI且合并心房颤动患者74例为研究对象,采用随机数字表法分为观察组和对照组,每组各37例;观察组采用胺碘酮治疗,对照组采用毛花苷丙治疗,评价两组治疗效果,比较两组房颤动控制率、窦性心律维持率、病死率及不良反应发生率。结果:观察组的显效率、总有效率分别为73.0%(18/37)、94.6%(27/37),明显高于对照组的48.6%(27/37)、73.0%(35/37),差异有统计学意义(P=0.032,P=0.021);房颤动控制率及窦性心律维持率分别为67.6%(25/37)、81.1%(30/37)明显高于对照组的43.2%(16/37)、45.9%(17/37),差异有统计学意义(P=0.035,P=0.002);病死率及不良反应发生率分别为5.4%(2/37)、10.8%(4/37)明显低于对照组的21.6%(8/37)、51.8%(19/37),差异有统计学意义(P=0.041,P0.001)。结论:胺碘酮治疗老年AMI伴心房颤动的临床疗效显著,药物不良反应的发生率较低,安全有效,值得在临床应用推广。     

不同消融方式对心房颤动患者凝血参数、心肌损伤以及生活质量的影响

摘要 目的：探讨不同消融方式对心房颤动患者凝血参数、心肌损伤以及生活质量的影响。方法：回顾性分析2018年1月至2019年7月在我院心血管内二科住院拟行消融手术的心房颤动患者200例的临床资料,根据消融方式分为射频消融（RFCA）组（n=99）和冷冻消融（CBA）组（n=101）,比较两组患者围术期指标、凝血参数、心肌损伤以及生活质量,记录两组术后并发症发生情况。结果：CBA组手术时间、消融时间短于RFCA组,冷冻最低温度低于RFCA组（P<0.05）。两组术后 24 h活化部分凝血活酶时间（APTT）降低,但CBA组高于RFCA组（P<0.05）,两组术后 24 h血管性假血友病因子（vWF）、D-二聚体（D-D）升高,但CBA组低于RFCA组（P<0.05）。两组术后 24 h肌酸激酶（CK）、肌酸激酶同工酶（CK-MB）、肌钙蛋白 I （TnI）较术前升高,且CBA组高于RFCA组（P<0.05）。两组术后3个月情感职能、躯体疼痛、生理机能、精神健康、活力、生理职能、健康状况、社会功能维度评分较术前升高,且CBA组高于RFCA组（P<0.05）。两组并发症发生率对比未见统计学差异（P>0.05）。结论：与RFCA相比,CBA治疗心房颤动,可缩短手术时间、消融时间,减轻对凝血功能的影响,提高患者生活质量,且不增加并发症发生率,但CBA对机体心肌损伤影响更大,临床应视患者具体情况选择合适的手术方法进行治疗。     

Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation

ObjectiveTo determine the extent to which implementation of an evidence based treatment, antithrombotic treatment in atrial fibrillation, is possible in general practice.DesignAudit and qualitative study of patients with atrial fibrillation and an educational intervention for patients judged eligible for antithrombotic treatment.SettingSouth east England.Subjects56 patients with a history of atrial fibrillation.InterventionsAssessment and interview to ascertain patients'' views on antithrombotic treatment.ResultsOut of 13 239 patients, 132 had a history of atrial fibrillation of which 100 were at risk of thromboembolism. After the study, 52 patients were taking warfarin. Of the remaining 48 patients (of whom 41 were taking aspirin), eight were too ill to participate, 16 were unable to consent, four refused the interview, and 20 declined warfarin. Patients declining warfarin were inclined to seek a higher level of benefit than those taking it, as measured by the minimal clinically important difference. Qualitative data obtained during the interviews suggested that patients'' health beliefs were important factors in determining their choice of treatment.ConclusionPatients’ unwillingness to take warfarin seemed to be a major factor in limiting the number who would eventually take it.

Key messages

• After a structured intervention only half of a group of apparently eligible patients ended up taking warfarin for their atrial fibrillation
• Implementation of warfarin treatment for patients with atrial fibrillation was constrained by patients who were either too ill to take the drug or were unable to give consent
• These constraints are compounded by the unwillingness of patients to reduce their risk by taking a proved drug
• The number needed to treat, a key statistic in evidence based medicine, probably often overestimates the value of treatment in routine general practice and may not be sufficient to persuade patients of the benefit of treatment

     

右室Tei指数与血清醛固酮水平对COPD患者发生房颤的预测价值研究

摘要 目的：探讨右室Tei指数、血清醛固酮水平对慢性阻塞性肺病(COPD)患者发生房颤的预测价值。方法：根据房颤的发生情况,将200例COPD患者分为房颤发生组和无房颤发生组。比较两组的病程、COPD严重程度、血清醛固酮(ALD)水平及右室Tei指数、肺动脉压、右心室横径的差异,分析右室Tei指数和ALD预测房颤发生的ROC曲线下面积、截断值、灵敏度及特异度。结果：房颤发生组病程(8.48±1.3和7.59±1.75)、右心室横径(40.52±2.74和36.27±2.4)、血清ALD(137.64±42.77和98.61±15.39)、右室Tei指数(0.37±0.12和0.31±0.07)、COPD、肺动脉高压的严重程度与无房颤发生组比较差异都有统计学意义(P<0.05)。logistic回归分析结果显示ALD、右室Tei指数、病程、和肺动脉高压程度为影响COPD患者发生房颤的独立影响因素。右室Tei指数预测房颤发生的ROC曲线下面积AUC=0.645,截断值为0.420,灵敏度为38.0%,特异度达到93.33%;ALD预测房颤发生的ROC曲线下面积为0.792,截断值为122.72 pg/mL,灵敏度为66.0%,特异度可达到98.0%。结论：右室Tei指数和血清醛固酮水平可作为慢性阻塞性肺病患者发生房颤的预测参考指标。     

Clinical Characteristics,Management, and Control of Permanent vs. Nonpermanent Atrial Fibrillation: Insights from the RealiseAF Survey

Background

Atrial fibrillation can be categorized into nonpermanent and permanent atrial fibrillation. There is less information on permanent than on nonpermanent atrial fibrillation patients. This analysis aimed to describe the characteristics and current management, including the proportion of patients with successful atrial fibrillation control, of these atrial fibrillation subsets in a large, geographically diverse contemporary sample.

Methods and Results

Data from RealiseAF, an international, observational, cross-sectional survey of 10,491 patients with atrial fibrillation, were used to characterize permanent atrial fibrillation (N = 4869) and nonpermanent atrial fibrillation (N = 5622) patients. Permanent atrial fibrillation patients were older, had a longer time since atrial fibrillation diagnosis, a higher symptom burden, and were more likely to be physically inactive. They also had a higher mean (SD) CHADS₂ score (2.2 [1.3] vs. 1.7 [1.3], p<0.001), and a higher frequency of CHADS₂ score ≥2 (67.3% vs. 53.0%, p<0.001) and comorbidities, most notably heart failure. Physicians indicated using a rate-control strategy in 84.2% of permanent atrial fibrillation patients (vs. 27.5% in nonpermanent atrial fibrillation). Only 50.2% (N = 2262/4508) of permanent atrial fibrillation patients were controlled. These patients had a longer time since atrial fibrillation diagnosis, a lower symptom burden, less obesity and physical inactivity, less severe heart failure, and fewer hospitalizations for acute heart failure than uncontrolled permanent atrial fibrillation patients, but with more arrhythmic events. The most frequent causes of hospitalization in the last 12 months were acute heart failure and stroke.

Conclusion

Permanent atrial fibrillation is a high-risk subset of atrial fibrillation, representing half of all atrial fibrillation patients, yet rate control is only achieved in around half. Since control is associated with lower symptom burden and heart failure, adequate rate control is an important target for improving the management of permanent atrial fibrillation patients.     

Polysomnography in AF patients without prior diagnosis of obstructive sleep apnea reveals significant sleep abnormality: A strong case for screening in all patients with atrial fibrillation?

BackgroundObstructive sleep apnea (OSA) and atrial fibrillation (AF) are known to often coexist together. However, whether all patients with AF should be screened for sleep abnormalities is not clear. No previous study has examined the association of asymptomatic OSA with AF.ObjectiveThis study sought to determine the prevalence of asymptomatic OSA in patients with persistent AF and whether asymptomatic OSA is an independent risk factor for atrial fibrillation.MethodPatients with persistent AF without a prior diagnosis of OSA and asymptomatic for sleep abnormalities were prospectively enrolled over 12 months. All patients underwent polysomnography after informed consent. Patients without AF or OSA who underwent polysomnography during the same period served as controls.ResultsA total of 97 patients were studied; 50 were in the case group (patients with persistent AF) and 47 were in the control group (patients in sinus rhythm). Asymptomatic OSA was diagnosed on polysomnography in 72% of patients in the AF group and 17% of the control population. Multivariable analysis of factors including diabetes, hypertension, coronary artery disease, hypothyroidism, prior MI, and asymptomatic OSA, suggested asymptomatic OSA as an independent factor associated with AF.ConclusionA significant proportion (72%) of patients with persistent AF have underlying asymptomatic OSA. Sleep abnormality thus has a strong association with AF even in patients who are asymptomatic for OSA. Screening for OSA may be advised for all patients with AF, as this may have significant implications for management.     

心房颤动对不同时间窗内急性缺血性脑卒中患者静脉溶栓疗效的对比研究

目的:探讨与对比心房颤动对不同时间窗内急性缺血性脑卒中患者静脉溶栓疗效的影响。方法:选择2014年8月到2016年5月在我院进行诊治的急性缺血性脑卒中患者98例,其中卒中前已诊断心房颤动定义为慢性心房颤动组(n=50),入院后诊断心房颤动者为新发心房颤动组(n=48);两组都给予重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗,记录两组预后情况。结果:两组患者的性别、年龄、时间窗、合并疾病、血糖与甘油三酯含量对比无明显差异(P0.05)。慢性心房颤动组与新发心房颤动组的有效率分别为94.0%和95.8%,组间比较差异无统计学意义(P0.05)。慢性心房颤动组与新发心房颤动组治疗后的m RS评分分别为6.22±1.83分和6.29±1.45分,都明显低于治疗前的9.24±1.31分和9.19±1.52分(P0.05),组间对比无明显差异(P0.05)。慢性心房颤动组的症状性脑出血与非症状性脑出血发生率分别为4.0%和2.0%,都明显低于新发心房颤动组的14.6%和12.5%(P0.05)。结论:发病4.5h之内静脉溶栓急性缺血性脑卒中是安全有效的,新发心房颤动不影响患者静脉溶栓后的神经功能结局,但是会增加症状性脑出血与非症状性脑出血,需要加强预防性管理。     

中老年黄斑变性患者跌倒风险与视力的关系及对生存质量的影响

摘要 目的：分析中老年黄斑变性患者跌倒风险与视力的关系及其影响因素,并分析其对生存质量的影响。方法：研究对象为我院2018年1月~2020年12月期间收治的中老年黄斑变性患者95例,采用修订版社区老年人跌倒危险评估工具（MFROP-COM）评估患者跌倒风险。采用世界卫生组织生存质量量表（WHOQOL-BREAF）评价患者的生存质量。采用本院自制的调查问卷获取患者的临床资料。中老年黄斑变性患者跌倒风险的影响因素采用单因素及多因素Logistic回归分析。结果：本次研究共发放调查问卷95份,回收有效问卷95份,回收率100.00%。其中存在跌倒风险的患者38例（40.00%）。无跌倒风险的患者视力、生存质量各领域评分均优于有跌倒风险的患者（P<0.05）。单因素分析显示：中老年黄斑变性患者跌倒风险与视力、文化程度、年龄、家中安全行走、婚姻状况、居住方式、日常生活能力、居家环境安全、足部疾病、社区安全行走有关（P<0.05）。多因素Logistic回归分析结果显示：日常生活能力、视力、家中安全行走、足部疾病、社区安全行走、居家环境安全是中老年黄斑变性患者跌倒风险的影响因素（P<0.05）。结论：中老年黄斑变性患者存在跌倒风险的人数占比较高,且跌倒风险受多种因素影响,有跌倒风险的患者生存质量更低,因此临床需积极评估并帮助此类患者建立科学防跌倒生活行为,对改善中老年黄斑变性患者生存质量具有重要意义。     

Efficacy and safety of catheter ablation for atrial fibrillation in congenital heart disease – A systematic review and meta-analysis

BackgroundPrevalence of atrial fibrillation (AF) in patients with congenital heart disease (CHD) is on the rise. Anti-arrhythmic drugs are usually the first line of treatment in CHD, however, it is often ineffective and poorly tolerated. We aimed to perform a systematic review to assess the efficacy and safety of catheter ablation for AF in CHD.MethodsWe performed a comprehensive search on catheter ablation for atrial fibrillation in congenital heart disease up until July 2019 through several electronic databases.ResultsAblation of AF in patients with CHD had a modest 12 months AF freedom ranging from 32.8% to 63%, which can be increased by subsequent/repeat ablation. The complexity of CHD appears to have a significant effect on a study but not in others. Catheter ablation in ASD and persistent left superior vena cava had a high success rate. Overall, catheter ablation is safe whichever the type of CHD is.ConclusionCatheter ablation for AF in CHD had modest efficacy that can be increased by subsequent/repeat ablation and it also has an excellent safety profile. Ablation in complex CHD could also have similar efficacy, however, it is preferably done by experts in a high volume tertiary center.     

益气养阴活血化瘀方对心力衰竭合并房颤患者血清CRP，BNP，CK-MB及cTnI水平的影响及其疗效观察

目的:探讨益气养阴活血化瘀方治疗心力衰竭合并房颤的临床疗效。方法:收集2014年3月-2015年9月我院收治的158例充血性心力衰竭合并房颤的患者158例为研究对象,随机分为对照组和实验组,每组79例。对照组患者采取常规治疗,实验组患者采用益气养阴活血化瘀方治疗。观察并比较两组患者治疗前后超敏C反应蛋白(CRP)、脑钠素(BNP),CK-MB及肌钙蛋白(cTnI)水平的变化情况。结果:治疗后,与对照组相比,实验组LVEDD、LVESD明显低于对照组,而LVEF明显增高,差异具有统计学意义(P0.05);治疗后实验组患者的CK-MB、pro-BNP、cTnI及CRP水平明显低于对照组,差异具有统计学意义(P0.05)。实验组随访末期死亡率、非致死性心力衰竭及心源性休克发生率均低于对照组,差异具有统计学意义(P0.05);随访末期内建立侧支循环明显多于对照组,差异具有统计学意义(P0.05)。结论:益气养阴活血化瘀方可以有效抑制充血性心力衰竭合并房颤患者术后心脏重塑,改善左心室收缩功能,降低不良事件发生。     

Obesity,Metabolic Syndrome and Risk of Atrial Fibrillation: A Swedish,Prospective Cohort Study

AimWe aimed to investigate whether different measures of obesity could similarly predict atrial fibrillation, and whether the atrial fibrillation risk associated with obesity is dependent on presence of metabolic syndrome.ResultsDuring a mean follow-up of 13.6 years, 285 incident atrial fibrillation cases were recorded. One standard deviation increment of each obesity measure was associated with increased atrial fibrillation risk as: body mass index 1.25 (1.12 – 1.40), waist circumference 1.35 (1.19 – 1.54) and sagittal abdominal diameter 1.28 (1.14 – 1.44). Compared to normal weight subjects without metabolic syndrome, increased atrial fibrillation risk was noted for overweight subjects with metabolic syndrome, 1.67 (1.16 – 2.41), obese subjects without metabolic syndrome, 1.75 (1.11 – 2.74) and obese subjects with metabolic syndrome, 1.92 (1.34 – 2.74). Compared to subjects with normal waist circumference without metabolic syndrome, subjects with elevated waist circumference and metabolic syndrome suffered increased atrial fibrillation risk, 2.03 (1.44 – 2.87).ConclusionsBody mass index, waist circumference and sagittal abdominal diameter could similarly predict atrial fibrillation. Obesity was associated with an increased atrial fibrillation risk regardless of metabolic syndrome, whereas overweight and elevated waist circumference was associated with increased atrial fibrillation risk only if metabolic syndrome was present.     

Apocynin: a potent NADPH oxidase inhibitor for the management of atrial fibrillation

Abstract

Oxidative stress in atrial tissue may be causally related to atrial fibrillation as suggested by clinical and animal studies. Reactive oxygen species (ROS) are known to play a key role in fibrosis and the induction of after-depolarization and triggered activity. Therefore, suppressing oxidative stress may have a potential beneficial role in the management of atrial fibrillation. Since increased NADPH oxidase activity is shown to play a key role in generation of ROS in atrial tissue and in atrial fibrillation, our proposed strategy to target upstream inhibition of ROS production by inhibition of NADPH oxidase activity may provide a novel approach to prevent atrial fibrillation recurrences. We hypothesize that apocynin could be effective against atrial fibrillation, by virtue of its potent inhibitory effect of a major oxidative system (i.e. NADPH oxidase) combined with its demonstrated anti-inflammatory, antifibrotic and antihypertensive effects which partially are driven from its antioxidant property. Atrial fibrillation is known to be initiated by the interaction of these multiple factors.